Compugen (NASDAQ:CGEN) Upgraded by StockNews.com to Buy

Compugen (NASDAQ:CGEN) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

Separately, Truist Financial reduced their price objective on shares of Compugen from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 21st.

Compugen Stock Performance

CGEN opened at $1.75 on Thursday. The company’s 50 day simple moving average is $2.06 and its 200 day simple moving average is $2.12. Compugen has a 1 year low of $0.53 and a 1 year high of $3.03. The stock has a market capitalization of $151.59 million, a PE ratio of -9.21 and a beta of 2.71.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. The business had revenue of $2.56 million for the quarter, compared to analysts’ expectations of $2.79 million. As a group, sell-side analysts expect that Compugen will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of Compugen

An institutional investor recently bought a new position in Compugen stock. Heron Bay Capital Management acquired a new position in Compugen Ltd. (NASDAQ:CGEN) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.